The effects of antibody treatment on regulatory CD4+CD25+ T cells

Transplant Immunology

Volumn 19, Issue 1, 2008, Pages 37-44

  Yi, Huanfa ^a,b   Zhang, Jialin ^c   Zhao, Yong ^a,b  

^a INSTITUTE OF ZOOLOGY   (China)

^b China US Joint Research Center for Life Sciences   (China)

^c First University Hospital   (China)

Author keywords

Antibodies; Immune tolerance; Immunosuppression; Regulatory T cells; Transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; DACLIZUMAB; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 45RB; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY JJ 316; MONOCLONAL ANTIBODY OX 40; OKT 4; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADJUVANT ARTHRITIS; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CLINICAL TRIAL; DRUG EFFECT; HUMAN; KIDNEY GRAFT REJECTION; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKIN ALLOGRAFT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSPLANTATION TOLERANCE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; GRAFT SURVIVAL; HUMANS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 40849085424     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.12.001     Document Type: Review

References (111)

1. Lechler R.I., Sykes M., Thomson A.W., and Turka L.A. Organ transplantation - how much of the promise has been realized?. Nat Med 11 (2005) 605-613
2. Sykes M. Mixed chimerism and transplant tolerance. Immunity 14 (2001) 417-424
3. Lechler R.I., Garden O.A., and Turka L.A. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 3 (2003) 147-158
4. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
5. Walsh P.T., Taylor D.K., and Turka L.A. Tregs and transplantation tolerance. J Clin Invest 114 (2004) 1398-1403
6. Waldmann T.A. A novel means of favorably tipping the balance between cytopathic and regulatory T cells. Immunity 19 (2003) 465-466
7. Waldmann H., and Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?. Annu Rev Immunol 16 (1998) 619-644
8. Luke P.P., O'Brien C.A., Jevnikar A.M., and Zhong R. Anti-CD45RB monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 1 (2001) 533-543
9. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3 (2003) 123-132
10. Cobbold S.P. T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B Biol Sci 360 (2005) 1695-1705
11. Graca L., Le Moine A., Cobbold S.P., and Waldmann H. Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol Res 28 (2003) 181-191
12. Sakaguchi S., and Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 24 (2005) 211-226
13. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
14. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 12 (2006) 627-635
15. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-243
16. George J.F., and Thomas J.M. The molecular mechanisms of veto mediated regulation of alloresponsiveness. J Mol Med 77 (1999) 519-526
17. MacDonald H.R. Development and selection of NKT cells. Curr Opin Immunol 14 (2002) 250-254
18. Zhang Z.X., Yang L., Young K.J., DuTemple B., and Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6 (2000) 782-789
19. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol 4 (2004) 841-855
20. Sutmuller R.P., Offringa R., and Melief C.J. Revival of the regulatory T cell: new targets for drug development. Drug Discov Today 9 (2004) 310-316
21. Taylor P.A., Noelle R.J., and Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193 (2001) 1311-1318
22. Hoffmann P., Ermann J., Edinger M., Fathman C.G., and Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196 (2002) 389-399
23. Graca L., Thompson S., Lin C.Y., Adams E., Cobbold S.P., and Waldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 168 (2002) 5558-5565
24. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166 (2001) 3789-3796
25. Roncarolo M.G., Gregori S., and Levings M. Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells. Novartis Found Symp 252 (2003) 115-127 discussion 127-131, 203-110
26. Zelenika D., Adams E., Humm S., Lin C.Y., Waldmann H., and Cobbold S.P. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev 182 (2001) 164-179
27. Zhang L., and Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 211 (2007) 590-597
28. Watanabe T., Yoshida M., Shirai Y., Yamori M., Yagita H., Itoh T., et al. Administration of an antigen at a high dose generates regulatory CD4+ T cells expressing CD95 ligand and secreting IL-4 in the liver. J Immunol 168 (2002) 2188-2199
29. Gondek D.C., Lu L.F., Quezada S.A., Sakaguchi S., and Noelle R.J. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174 (2005) 1783-1786
30. Asseman C., Mauze S., Leach M.W., Coffman R.L., and Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1004
31. Shevach E.M., McHugh R.S., Piccirillo C.A., and Thornton A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182 (2001) 58-67
32. Piccirillo C.A., Letterio J.J., Thornton A.M., McHugh R.S., Mamura M., Mizuhara H., et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 196 (2002) 237-246
33. Cederbom L., Hall H., and Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30 (2000) 1538-1543
34. Zhou J., Carr R.I., Liwski R.S., Stadnyk A.W., and Lee T.D. Oral exposure to alloantigen generates intragraft CD8+ regulatory cells. J Immunol 167 (2001) 107-113
35. Genestier L., Fournel S., Flacher M., Assossou O., Revillard J.P., and Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 91 (1998) 2360-2368
36. Hale D.A., Gottschalk R., Maki T., and Monaco A.P. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 65 (1998) 473-479
37. Kawai T., Cosimi A.B., Colvin R.B., Powelson J., Eason J., Kozlowski T., et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59 (1995) 256-262
38. Chung D.T., Korn T., Richard J., Ruzek M., Kohm A.P., Miller S., et al. Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. Int Immunol 19 (2007) 1003-1010
39. Ogawa N., Minamimura K., Kodaka T., and Maki T. Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. J Autoimmun 26 (2006) 225-231
40. Minamimura K., Gao W., and Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 176 (2006) 4125-4132
41. Ogawa N., List J.F., Habener J.F., and Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53 (2004) 1700-1705
42. Yi H., Zhen Y., Jiang L., Zheng J., and Zhao Y. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol Immunol 3 (2006) 189-195
43. Basadonna G.P., Auersvald L., Khuong C.Q., Zheng X.X., Kashio N., Zekzer D., et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 95 (1998) 3821-3826
44. Luke P.P., Deng J.P., Lian D., O'Connell P.J., Garcia B., Jevnikar A.M., et al. Prolongation of allograft survival by administration of anti-CD45RB monoclonal antibody is due to alteration of CD45RBhi: CD45RBlo T-cell proportions. Am J Transplant 6 (2006) 2023-2034
45. Luke P.P., Deng J.P., O'Brien C.A., Everest M., Hall A.V., Chakrabarti S., et al. Alteration in CD45RBhi/CD45RBlo T-cell ratio following CD45RB monoclonal-antibody therapy occurs by selective deletion of CD45RBhi effector cells. Transplantation 76 (2003) 400-409
46. Fecteau S., Basadonna G.P., Freitas A., Ariyan C., Sayegh M.H., and Rothstein D.M. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2 (2001) 58-63
47. Salvalaggio P.R., Camirand G., Ariyan C.E., Deng S., Rogozinski L., Basadonna G.P., et al. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol 176 (2006) 2292-2298
48. Deng S., Moore D.J., Huang X., Mohiuddin M., Lee M.K.t., Velidedeoglu E., et al. Antibody-induced transplantation tolerance that is dependent on thymus-derived regulatory T cells. J Immunol 176 (2006) 2799-2807
49. Gregori S., Mangia P., Bacchetta R., Tresoldi E., Kolbinger F., Traversari C., et al. An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J Exp Med 201 (2005) 1293-1305
50. Okita R., Yamaguchi Y., Emi A., Matsuura K., and Toge T. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. Oncol Rep 17 (2007) 1429-1435
51. Nashan B., Moore R., Amlot P., Schmidt A.G., Abeywickrama K., and Soulillou J.P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350 (1997) 1193-1198
52. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338 (1998) 161-165
53. Stephens L.A., and Anderton S.M. Comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells". J Immunol 177 (2006) 2036 author reply 2037-2038
54. Zelenay S., and Demengeot J. Comment on "Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells". J Immunol 177 (2006) 2036-2037 author reply 2037-2038
55. Bigenzahn S., Blaha P., Koporc Z., Pree I., Selzer E., Bergmeister H., et al. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 5 (2005) 1237-1247
56. Martin P.J., Pei J., Gooley T., Anasetti C., Appelbaum F.R., Deeg J., et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 10 (2004) 552-560
57. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194 (2001) 823-832
58. Jones E., Dahm-Vicker M., Simon A.K., Green A., Powrie F., Cerundolo V., et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2 (2002) 1
59. Nagai H., Horikawa T., Hara I., Fukunaga A., Oniki S., Oka M., et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 13 (2004) 613-620
60. Kohm A.P., McMahon J.S., Podojil J.R., Begolka W.S., DeGutes M., Kasprowicz D.J., et al. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 176 (2006) 3301-3305
61. Game D.S., Hernandez-Fuentes M.P., and Lechler R.I. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 5 (2005) 454-464
62. Kreijveld E., Koenen H.J., Klasen I.S., Hilbrands L.B., and Joosten I. Following Anti-CD25 Treatment, A Functional CD4+CD25+ Regulatory T-Cell Pool Is Present in Renal Transplant Recipients. Am J Transplant 7 (2007) 249-255
63. Eisenberg R. Update on rituximab. Ann Rheum Dis 64 Suppl 4 (2005) iv55-iv57
64. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17 (2005) 550-557
65. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5 (2006) 18-24
66. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122 (2007) 62-74
67. Schulze-Koops H., and Lipsky P.E. Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. Curr Dir Autoimmun 2 (2000) 24-49
68. Pullar C.E., Morris P.J., and Wood K.J. Altered proximal T-cell receptor signalling events in mouse CD4+ T cells in the presence of anti-CD4 monoclonal antibodies: evidence for reduced phosphorylation of Zap-70 and LAT. Scand J Immunol 57 (2003) 333-341
69. Pearson T.C., Madsen J.C., Larsen C.P., Morris P.J., and Wood K.J. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54 (1992) 475-483
70. Saitovitch D., Bushell A., Mabbs D.W., Morris P.J., and Wood K.J. Kinetics of induction of transplantation tolerance with a nondepleting anti-Cd4 monoclonal antibody and donor-specific transfusion before transplantation. A critical period of time is required for development of immunological unresponsiveness. Transplantation 61 (1996) 1642-1647
71. Saitovitch D., Morris P.J., and Wood K.J. Recipient cells expressing single donor MHC locus products can substitute for donor-specific transfusion in the induction of transplantation tolerance when pretreatment is combined with anti-Cd4 monoclonal antibody. Evidence for a vital role of Cd4+ T cells in the induction of tolerance to class I molecules. Transplantation 61 (1996) 1532-1538
72. Bushell A., Morris P.J., and Wood K.J. Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol 25 (1995) 2643-2649
73. Kingsley C.I., Karim M., Bushell A.R., and Wood K.J. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 168 (2002) 1080-1086
74. Karim M., Kingsley C.I., Bushell A.R., Sawitzki B.S., and Wood K.J. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 172 (2004) 923-928
75. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15 (1997) 1567-1574
76. Countouriotis A., Moore T.B., and Sakamoto K.M. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20 (2002) 215-229
77. Isaacs J.D., Watts R.A., Hazleman B.L., Hale G., Keogan M.T., Cobbold S.P., et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340 (1992) 748-752
78. Lockwood C.M., Thiru S., Isaacs J.D., Hale G., and Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341 (1993) 1620-1622
79. Hale G., Jacobs P., Wood L., Fibbe W.E., Barge R., Novitzky N., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26 (2000) 69-76
80. Calne R., Moffatt S.D., Friend P.J., Jamieson N.V., Bradley J.A., Hale G., et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68 (1999) 1613-1616
81. Kirk A.D., Hale D.A., Mannon R.B., Kleiner D.E., Hoffmann S.C., Kampen R.L., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76 (2003) 120-129
82. Knechtle S.J., Pirsch J.D., Fechner Jr. J.H., Becker B.N., Friedl A., Colvin R.B., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 3 (2003) 722-730
83. Valentin H., Gelin C., Coulombel L., Zoccola D., Morizet J., and Bernard A. The distribution of the CDW52 molecule on blood cells and characterization of its involvement in T cell activation. Transplantation 54 (1992) 97-104
84. Watanabe T., Masuyama J., Sohma Y., Inazawa H., Horie K., Kojima K., et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 120 (2006) 247-259
85. Masuyama J., Kaga S., Kano S., and Minota S. A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells. J Immunol 169 (2002) 3710-3716
86. Parker D.C., Greiner D.L., Phillips N.E., Appel M.C., Steele A.W., Durie F.H., et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 92 (1995) 9560-9564
87. Zheng X.X., Markees T.G., Hancock W.W., Li Y., Greiner D.L., Li X.C., et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 162 (1999) 4983-4990
88. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
89. Honey K., Cobbold S.P., and Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 163 (1999) 4805-4810
90. Kirk A.D., Burkly L.C., Batty D.S., Baumgartner R.E., Berning J.D., Buchanan K., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5 (1999) 686-693
91. Kenyon N.S., Chatzipetrou M., Masetti M., Ranuncoli A., Oliveira M., Wagner J.L., et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 96 (1999) 8132-8137
92. Graca L., Honey K., Adams E., Cobbold S.P., and Waldmann H. Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 165 (2000) 4783-4786
93. Zheng X.X., Sanchez-Fueyo A., Domenig C., and Strom T.B. The balance of deletion and regulation in allograft tolerance. Immunol Rev 196 (2003) 75-84
94. Sanchez-Fueyo A., Weber M., Domenig C., Strom T.B., and Zheng X.X. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 168 (2002) 2274-2281
95. Lee I., Wang L., Wells A.D., Dorf M.E., Ozkaynak E., and Hancock W.W. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 201 (2005) 1037-1044
96. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002) 1692-1698
97. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., and Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 111 (2003) 409-418
98. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
99. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 (1997) 2947-2954
100. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 (2003) 1202-1208
101. Bisikirska B., Colgan J., Luban J., Bluestone J.A., and Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115 (2005) 2904-2913
102. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
103. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171 (2003) 3348-3352
104. Urakami H., Ostanin D.V., Hunig T., and Grisham M.B. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 38 (2006) 3244-3246
105. Rodriguez-Palmero M., Franch A., Castell M., Pelegri C., Perez-Cano F.J., Kleinschnitz C., et al. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 33 (2006) 110-118
106. Beyersdorf N., Hanke T., Kerkau T., and Hunig T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 64 Suppl 4 (2005) iv91-iv95
107. Schmidt J., Elflein K., Stienekemeier M., Rodriguez-Palmero M., Schneider C., Toyka K.V., et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140 (2003) 143-152
108. Lin C.H., and Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 33 (2003) 626-638
109. Grimbert P., Bouguermouh S., Baba N., Nakajima T., Allakhverdi Z., Braun D., et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 177 (2006) 3534-3541
110. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A.D., and Colombo M.P. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105 (2005) 2845-2851
111. Adams A.B., Shirasugi N., Durham M.M., Strobert E., Anderson D., Rees P., et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51 (2002) 265-270